Early drug treatment to prevent low platelets before stem cell transplant
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests whether giving a medicine called rhTPO early can help prevent low blood platelets, a common side effect of the chemotherapy used to prepare your body for a stem cell transplant. The goal is to help you recover faster and reduce the need for platelet transfusions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with multiple myeloma or B-cell lymphoma and are planning to have a stem cell transplant using your own cells.
- Your blood platelet count is at least 80,000 per microliter.
- Your heart, liver, and kidneys are healthy enough for the treatment.
- You have not had blood clots, liver cirrhosis, uncontrolled infections, or bone marrow scarring.
- You are not pregnant or breastfeeding and you are not allergic to the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a drug called rhTPO can help collect your own stem cells for a transplant to treat acute leukemia. The goal is to improve stem cell collection so the transplant can be more successful.
This trial tests a drug called romiplostim for patients whose platelet counts stay very low (below 30) for a long time after chemotherapy, even after other treatments have failed. The goal is to see if romiplostim can help raise your platelet count to a safer level.
This trial tests a drug called romiplostim to help raise platelet levels in children and young adults (ages 6–24) whose platelets drop due to chemotherapy. It’s for those with solid tumors or other non-marrow cancers who are still getting strong treatment.
This Phase 2 study tests eltrombopag to help people with low platelet counts caused by chemotherapy (which can increase bleeding risk). It looks at whether raising platelets can reduce bleeding problems and help you stay on track with care.
This trial compares two drugs, romiplostim and rhTPO, to help increase platelet counts after a stem cell transplant in people with MDS or aplastic anemia. The goal is to see which drug works better at reducing the need for platelet transfusions.
This trial tests whether adding a medication that helps the body make more platelets (called rhTPO) to the usual treatment (cyclosporine) can improve platelet counts and reduce bleeding in people with a type of bone marrow disorder called lower-risk MDS. It may help those who have very low platelets and are at risk of bleeding.
Hear when a new Hematopoietic Stem Cell Mobilization trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.